::: Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial
therapeutic cervical cancer vaccine, DNA vaccine doses, intermediate dose cohort, therapeutic vaccine targets, induction of antigen-specific immune responses, DNA vaccine targeting, DNA vaccine design, humoral immune responses, initial lowest dose cohort

::: Repros Submits Response to FDA Regarding Androxal® Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility
Repros Therapeutics focuses, Company noted, male fertility, Preserve Fertility, clinical development, Annual BIO CEO, Treatment of Hypogonadal Men Wishing, clinical trials, fertility impact of Androxal, clear clinical path

::: Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
assessment of oral laquinimod, efficacy of laquinimod, tolerability of laquinimod, market potential of laquinimod, Teva Pharmaceutical Industries, Teva extended, CEO Active Biotech, Phase III study, global Phase III clinical trials, treatment of RRMS

::: Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development
clinical development programs, Trevena Names David Soergel, joining Trevena, shaping Trevena, clinical training, clinical strategy, lead drug development efforts, cutting edge of biased ligand drug discovery, clinical evaluation, chief executive officer of Trevena

::: Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease
Targacept cautions, trademark of Targacept, Forward-Looking Statements, Disease biomarkers, Conduct Biomarker Research, grant-funded research, unique research, research platform, research agenda, Fox Foundation